Pharma GCC pay is moving for a reason IT isn’t

The tidy story of the moment is that senior GCC pay has stabilised. In IT and BFSI, our own closes mostly agree. But run the same read across senior pharma roles and the line is still rising. The temptation is to explain it with the same forces, an AI premium, a platform race, and that explanation misreads what's actually happening. The pharma driver has little to do with technology.

It's regulatory. The seats commanding the premium are the ones that carry compliance-grade accountability: pharmacovigilance leadership, regulatory affairs, quality and validation, clinical-data governance. These are roles where a mis-hire is more than expensive. It becomes a finding, an audit, a submission at risk. The people who can hold that responsibility, at scale, from an offshore centre, are genuinely scarce, and the price reflects it.

That scarcity has a specific shape. India's life-sciences and pharma bench is large and growing. What's thin is the layer that can sign its name to a regulated deliverable: a safety report a health authority will read, a validation package an inspector will open, a submission that carries a company's market access. Depth at the practitioner level doesn't translate into depth at the accountable level, and it's the accountable level that GCCs are now building.

For years, pharma GCCs in India were staffed mainly for cost arbitrage on transactional work: case processing, data entry into safety databases, document formatting for submissions. That work still runs, but the mandate has shifted upward. Parent organisations have been moving decision-grade functions offshore, the judgment calls themselves, beyond the throughput, and that migration is what pulled senior regulatory roles into the Indian market at pace.

Several forces stack on top of each other here. Global drug pipelines have widened, which multiplies the volume of pharmacovigilance and regulatory work per approved product. Health authorities across major markets have tightened expectations on drug-safety reporting and data integrity, so the burden per submission has grown heavier. And the industry's move toward complex modalities, biologics, cell and gene therapies, brings compliance regimes that need people who have actually operated inside them, not people learning on the requisition.

Put those together and demand for accountable regulatory leadership has been climbing faster than the pool that can serve it. When several GCCs in the same city are all standing up or scaling pharmacovigilance and regulatory-affairs teams at once, they compete for the same short list of qualified leaders, and the offers move accordingly.

The pressure pools in a handful of functions where regulatory accountability is personal and non-transferable. Pharmacovigilance and drug-safety leadership sit at the top of that list: the people who own signal detection, aggregate safety reporting, and the qualified-person responsibilities that carry legal weight in regulated markets. Regulatory affairs strategy comes next, the professionals who plan and defend a submission across multiple health authorities.

Alongside them sit clinical-data management and clinical-data governance, where the scarce skill is standards-grade rigour under audit, and GxP and quality-compliance leadership, the validation, computer-system-validation, and quality-assurance heads whose sign-off gates whether a process is inspection-ready. What these seats share is that the work can't be delegated away from the named owner. An inspector holds a specific person accountable, and that accountability doesn't scale by adding headcount underneath.

Most published India-GCC benchmarks are dominated by technology roles, because that's where the volume is. When a pharma centre sets a regulatory-leadership band from that basket, it inherits a distribution shaped by a segment whose scarcity works differently. The result is a number that looks defensible and lands a rung or two under where the actual candidates are being courted.

The mechanism is worth being precise about. A cross-sector GCC survey blends software engineers, product managers, and platform leads into a single senior-band figure, then a pharma centre reads across to price a pharmacovigilance head from the same table. The two roles share a job level and almost nothing else. Engineering supply is deep and priced by a well-fed pipeline; accountable regulatory supply is thin and priced by who else is hiring for it this quarter. Reading one off the other imports the wrong distribution entirely.

The correction is to benchmark the seat itself: price regulatory-side pharma roles against the narrow pool that can actually fill them, and treat the broad GCC survey as background only. When the market data you buy is a tech basket wearing a GCC label, it'll describe your engineering hires accurately and mislead you on every regulatory one.

For a CHRO or a compensation committee, the practical exposure is a budget line that reads as one thing and behaves as another. A single “senior GCC” band assumes the roles inside it share a market. In a pharma centre standing up regulatory leadership alongside its technology functions, that assumption breaks at exactly the seats where a lost hire is most damaging, and the damage goes beyond a delayed fill. An under-filled pharmacovigilance or quality leadership seat is a compliance gap the parent organisation carries on its own risk register.

The fix is to separate the regulatory-side roles out and price them against their own pool, then hold the technology bands where the broader market says they should sit. That keeps spend accurate in both directions. It stops the over-correction of raising every senior offer to chase a scarcity that lives in four or five functions, and it stops the under-correction of losing those four or five functions to a competitor who priced them properly.

The test is whether the role carries named regulatory accountability, not the reporting line or the GCC label on the requisition. Ask what a health authority would hold this person responsible for. If the answer is a safety report, a validation package, a submission, or a data-integrity standard that an inspector can open and trace to one signature, the seat belongs in the regulatory market and should be priced against that thin pool.

Where the answer is delivery, throughput, or platform capability, the broader GCC benchmark serves you well, that pool is deep and the published averages track it. Two roles at the same seniority, in the same centre, can sit in different labour markets, and the way to find out is to look at what the role is accountable for under audit, not what level it occupies on the org chart. Get that reading right and the benchmark stops misfiring on the hires a pharma GCC can least afford to lose.